结直肠癌
免疫系统
基因
转录组
比例危险模型
免疫疗法
肿瘤科
生物
小桶
癌症
基因表达
癌症研究
计算生物学
生物信息学
免疫学
医学
内科学
遗传学
作者
Yi Lin,Y Chen,Lu Gan,Zhiyong Li,Shi Feng
标识
DOI:10.1080/00365521.2023.2281252
摘要
AbstractBackground Colorectal cancer (CRC) is the second leading cause of cancer-related death. Immunotherapy is one of the new options for cancer treatment. This study aimed to develop an immune-related signature associated with CRC.Methods We performed differential analysis to screen out the differentially expressed genes (DEGs) of The Cancer Genome Atlas–Colorectal Cancer (TCGA-CRC) datasets. Weighted gene co-expression network analysis (WGCNA) was performed to obtain the key module genes associated with differential immune cells. The candidate genes were obtained through overlapping key DEGs and key module genes. The univariate and multivariate Cox regression analyses were adopted to build a CRC prognostic signature. We further conducted immune feature estimation and chemotherapy analysis between two risk subgroups. Finally, we verified the expression of immune-related prognostic genes at the transcriptional level.Results A total of 61 candidate genes were obtained by overlapping key DEGs and key module genes associated with differential immune cells. Then, an immune-related prognostic signature was built based on the three prognostic genes (HAMP, ADAM8, and CD1B). The independent prognostic analysis suggested that age, stage, and RiskScore could be used as independent prognostic factors. Further, we found significantly higher expression of three prognostic genes in the CRC group compared with the normal group. Finally, real-time polymerase chain reaction verified the expression of three genes in patients with CRC.Conclusion The prognostic signature comprising HAMP, ADAM8, and CD1B based on immune cells was established, providing a theoretical basis and reference value for the research of CRC.Keywords: Colorectal cancerimmunotherapyprognostic signaturerisk subgroupsTCGA database Disclosure statementNo potential conflict of interest was reported by the authors.Additional informationFundingThis study was supported by the Xiamen Natural Science Foundation (No. 3502Z20227111).
科研通智能强力驱动
Strongly Powered by AbleSci AI